Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT03213652Phase 2Active Not Recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
PrincipalinvestigatorStart date: 2018-04-17

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

A P Chen

National Cancer Institute LAO

Related
8 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Sriram Yennu

M.D. Anderson Cancer Center

Related
12 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmMalignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

David Hui

M.D. Anderson Cancer Center

Related
9 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

David Hui, MD

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Giselle Sholler, MD

Beat Childhood Cancer at Atrium Health

Related
10 trials

Shared therapeutic areas:

Refractory NeuroblastomaWilms Tumor
Similarity Score2%

Anthony El-Khoueiry, MD

University of Southern California

Related
6 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Recurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Recurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

AeRang Kim, MD, PhD

Children's National Research Institute

Related
7 trials

Shared therapeutic areas:

Wilms Tumor
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT03213652Phase 2PrincipalInvestigator

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
Active Not Recruiting

All 1 trials loaded